Document 5kJ3m0Q6X9YEy13GZGyMVyMeJ

f , September ?, 195>6 Dr. Fran cis F. iieyroth Kettering Laboratory College of Medicine Un iversity of Cincinnati fden Avenue Cincinnati 19, Ohio Dear Dr. Heyroth: As you undoubtedly know, vre are considering a lar ge development program aimed at the commercialisation of the compound AP-3 (formerly designated as APd-l?8). In the course of th is v/ork, me '/ fill need to est ab lish ICC shipping regulation s far `th is m ater ial. Consequently, tinder separate cover Dr. Sugiaoto is shipping you 0.5 lb . of neat A?-3 and about one quart of bottoms from the r ectifyin g column in Detroit. Dr. hitherup lias seen and discussed the la t t e r m aterial vith Detroit personnel. This m aterial i s believed to contain toxic organic manganese compounds of un iden tified composition t o '.Thich personnel may be exposed. At presen t, vre are shipping AP-3 from' Orangeburg to Detroit labeled as a Class B poison . Since we expect the number and size of such shipments to in crease con siderably, we would appreciate your conducting the n ecessary t e st s to estab lish shipping regulation s at an ear ly date* Sin cer ely you rs, / r / ,- //Z/ / - V 1. Sh apiro Research Planning Coordin ator KO/jpn cc II. A. Kehoe ^ KE 0 0 1 8 2 7 6 N22224